Alternatives to Nemluvio If You Can't Fill Your Prescription

Nemluvio (nemolizumab-ilto) is the first IL-31 receptor antagonist approved for both prurigo nodularis (PN) and moderate-to-severe atopic dermatitis (eczema). But what if you can't access it — whether due to insurance denial, prior authorization delays, cost, or availability? The good news is that there are FDA-approved alternatives that your dermatologist can prescribe. Here's what you need to know.

Why Patients Look for Nemluvio Alternatives

There are several common reasons why a patient prescribed Nemluvio might need to consider alternatives:

Insurance denied prior authorization for Nemluvio

Cost is too high even with Galderma copay assistance

Allergic reaction or intolerance to Nemluvio

Nemluvio not adequately controlling symptoms after a trial period

Insurance plan requires step therapy — trying other treatments before covering Nemluvio

Alternative 1: Dupixent (Dupilumab) — For Both PN and Atopic Dermatitis

Dupixent (dupilumab) is the most established biologic alternative to Nemluvio. It's FDA-approved for both prurigo nodularis (adults) and atopic dermatitis (ages 6 months and older). Dupixent works by blocking IL-4 and IL-13 receptors, which are cytokine pathways closely linked to the IL-31 pathway targeted by Nemluvio.

Key comparison points vs. Nemluvio:

Dosing: Dupixent is given every 2 weeks; Nemluvio is monthly (every 4 weeks), which many patients prefer

Age range: Dupixent is approved for eczema from 6 months old; Nemluvio covers eczema from age 12 only

Mechanism: Dupixent targets IL-4/IL-13; Nemluvio directly blocks IL-31, the primary "itch cytokine," giving it a more targeted antipruritic effect

Head-to-head data: No direct comparison studies have been conducted; both are considered effective for their approved indications

Alternative 2: Adbry (Tralokinumab) — For Atopic Dermatitis Age 12+

Adbry (tralokinumab-ldrm) is an IL-13 antagonist approved for moderate-to-severe atopic dermatitis in patients 12 and older. It is not approved for prurigo nodularis. Adbry is given as an injection every 2 weeks initially; patients who respond well after 16 weeks may reduce to once monthly.

Adbry is a reasonable alternative for eczema patients who cannot access Nemluvio, though it targets IL-13 rather than IL-31, so its antipruritic profile may differ. It is also available as a prefilled pen or syringe.

Alternative 3: Ebglyss (Lebrikizumab) — For Atopic Dermatitis Age 18+

Ebglyss (lebrikizumab-lbkz) is another IL-13 antagonist, approved for adults 18 and older with moderate-to-severe atopic dermatitis. Like Adbry, it is not approved for prurigo nodularis. Ebglyss is injected every 2 weeks initially, transitioning to monthly maintenance dosing. It may be preferred by patients who want a monthly injection schedule similar to Nemluvio.

Alternative 4: Rinvoq (Upadacitinib) or Cibinqo (Abrocitinib) — Oral Options for Eczema

For patients who prefer an oral pill over injections, JAK1 inhibitors are FDA-approved options for moderate-to-severe atopic dermatitis. Rinvoq (upadacitinib) is available for adults and adolescents 12+, and Cibinqo (abrocitinib) is approved for adults and patients 12 and older.

Important caveat: Both JAK inhibitors carry boxed warnings for serious infections, malignancy, and cardiovascular events. They are generally reserved for patients who have not responded to or cannot tolerate biologics. These medications are also not approved for prurigo nodularis.

Non-Biologic Options: What If You Can't Access Any Biologic?

If biologics are out of reach due to cost or coverage, there are older systemic options used off-label for both PN and severe eczema, including:

Cyclosporine (off-label for PN): Short-term immunosuppressant; nephrotoxicity risk limits long-term use

Methotrexate (off-label): Inexpensive immunosuppressant used for severe PN and eczema; requires monitoring

Phototherapy (narrowband UVB): Light therapy can reduce itch and nodule burden in PN; requires multiple sessions per week at a clinic

Topical corticosteroids (TCS): First-line therapy; used in combination with Nemluvio for eczema; limited effectiveness for severe or widespread disease

Talk to Your Dermatologist — And Use medfinder to Locate What's Available

Choosing the right alternative depends on your diagnosis, age, insurance, and symptom profile. Your dermatologist is the best guide. And if your issue is simply locating a pharmacy that can fill any of these specialty medications, medfinder can call pharmacies near you to check availability, saving you hours of phone calls. Read more about why Nemluvio is hard to find for context on specialty pharmacy access.